EU approvals for olmesartan/amlodipine combo
This article was originally published in Scrip
Executive Summary
Daiichi Sankyohas received approvals in Europe for Sevikar, a fixed-dose, single-pill combination of olmesartan and amlodipine. The once-daily therapy was filed in 28 EU countries in September 2007 and has been approved in Germany, the Netherlands, Spain, France, the UK and Belgium. Other markets are expected to follow soon.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.